RA Capital | Team Page

PETER KOLCHINSKY, PhD

Managing Partner

Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Peter is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools and serves on the boards of publicly- and privately-held life science companies. Peter also leads the firm’s engagement and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policymakers, and industry. He served on the Board of Global Science and Technology for the National Academy of Sciences, is the author of The Entrepreneur’s Guide to a Biotech Startup, and frequently writes and speaks on the future of biotechnology innovation. Peter founded and serves as a Director of No Patient Left Behind, a non-profit advocate for healthcare reforms that would make today's medicines affordable to patients and promote the innovation that gives all of us hope for tomorrow. He holds a BA from Cornell University and a PhD in Virology from Harvard University.

RAJEEV SHAH

Managing Partner

Rajeev Shah is a Managing Partner at RA Capital Management. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. He is also active in the firm’s outreach efforts, speaking frequently both at industry events and in classrooms. Raj holds a BA from Cornell University, where he majored in Chemistry. Raj previously worked as a Senior Project Leader at Altus Pharmaceuticals, a spin-off company of Vertex Pharmaceuticals, where he assessed business processes and implemented system solutions across all areas of science. He is also an active member of the Big Brothers of Massachusetts Bay program.

ANDREW LEVIN, MD/PhD

Managing Director

Andrew Levin joined RA Capital Management in 2015 and is a Managing Director on the Investment Team and spearheads a drug discovery effort that has led to the formation of several new companies. Beginning in 2012, and prior to joining the Investment Manager, he was a Vice President at H.I.G. BioVentures. Previously he served as the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative. He holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School.

JOSH RESNICK, MD

Managing Director

Josh Resnick is a Managing Director at RA Capital Management. Josh’s primary responsibility at RA Capital is to lead early-stage private investments in and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools. Josh holds a BA in Chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. Josh was previously co-lead of SV Health Investors’ US Biotech practice where he was responsible for SV’s US venture creation activities, including its incubator, Brahma Discovery. Before SV, Josh was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund within Merck & Co. Prior to MRL Ventures, Josh was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Josh is currently a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital.

PIETER BOELHOUWER

Managing Director

Pieter Boelhouwer is a Managing Director of Strategy and Operations at RA Capital Management. Pieter’s primary responsibility at RA Capital is to lead major strategic initiatives and drive operational excellence across the firm. Pieter holds a BA from Trinity College and a JD from Yale Law School. Pieter previously worked as a consultant with McKinsey & Company, where he managed a variety of healthcare engagements, including pharmaceutical mergers, biotech product launch plans, OTC product rationalization, and hospital acquisitions. He held senior management positions at two successful start-up companies that were acquired and he has over 14 years of experience investing in the global healthcare sector, both as a Partner and Managing Director at Matrix Capital Management and as a General Partner and Managing Director at Ayer Capital Management, a healthcare-focused hedge fund. He also gained extensive legislative and public policy experience early in his career as a Legislative Aide to former United States Senator David Boren, and as a Domestic Policy Advisor to former Vice President Al Gore. Pieter has been recognized as one of the outstanding leaders in the U.S. through his selection as a White House Fellow, and he currently serves on the Board of Directors of the White House Fellows Foundation.

MARCUS ASCENZO

IT Operations Associate

Marcus Ascenzo is an IT Operations Associate RA Capital Management. Marcus’ primary responsibility at RA Capital is to provide technical assistance and support for issues related to computer systems, the network, and server environments. Marcus holds a BS in Information Technology from the University of Massachusetts, Lowell. He previously held positions as a Client Services Engineer at Coretelligent and a System Administrator at the Perkins School for the Blind.

DANIEL BAHCHELI

Associate Director

Daniel Bahcheli is an Associate Director at RA Capital Management. Daniel’s primary responsibility at RA Capital is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Daniel holds both a BS and MS degree in Microbiology and Immunology from McGill University. He worked previously as an Associate Managing Editor at EBSCO Health, and as a Medical Writer at IC Axon and Publicis Life Brands International.

PETER BALOGH

Junior Associate

Peter Balogh is a Junior Associate within the TechAtlas division of RA Capital Management. Peter’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Peter has a BS in Biology with minors in both Chemistry and Spanish for the Medical Professions from the University of North Carolina at Chapel Hill.

ADISON BECKER

Administrative Assistant

Adison is an Administrative Assistant at RA Capital Management. Adison’s primary responsibilities are to coordinate calendars, events, and company meetings for the Investment Team. Adison previously held posts as an Administrative Assistant and Office Manager at Dyer Brown Architects and as an Executive Assistant to the Principal and Office Manager at bKL Architecture. She has a BA in Communication Studies from University of Minnesota, Twin Cities.

RYAN BERRY, PhD

Analyst

Ryan Berry is an Analyst on the Investment Team at RA Capital Management. Ryan’s primary responsibility at RA Capital is to is to conduct due diligence on biotechnology companies. Prior to this role, Ryan was an Associate on the Cardio-Renal Team within the TechAtlas division of RA Capital, where he mapped competitive landscapes of drugs and medical devices for disease indications and capabilities, with a focus on coronary artery disease, stroke, and dyslipidemia. Ryan holds a BS in Biochemistry and Molecular Cell Biology from the University of Minnesota, Twin Cities, and a PhD in Molecular, Cellular and Developmental Biology from Yale University. His doctoral research focused on cellular mechanisms of adipogenesis.

MATT BEVERLY, PhD

Senior Software Engineer

Matt Beverly is a Senior Software Engineer at RA Capital Management. Matt’s primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Matt has a BA in Biology with minors in Mathematics and Physics from Ithaca College, a Master of Science in Bioinformatics from Northeastern University, and a PhD in Molecular Biology with a specialization in quantitative biology from Brandeis University. Matt comes to RA from Localytics where he served as a Senior Software Engineer for the past two years. Prior to Localytics, Matt served as software engineer at Mathworks.

ASTHA BILIMORIA

Research Assistant

Astha is a Research Assistant at RA Capital Management. Astha’s primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Astha’s previous experience includes Research Assistant roles at Clark University and Corbus Pharma. Astha holds a BA in Biochemistry and Molecular Biology (with a minor in Physics) from Clark University.

GUNES BOZKURT, PhD

Associate

Gunes Bozkurt is an Associate within the TechAtlas division of RA Capital Management. Gunes' primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Gunes joins us from Boston Children’s Hospital where she served as a scientist within the PCMM Program. Her research focused on biophysical characterization of different amyloid fibrils. Gunes holds a BSc in Biological Sciences and Bioengineering from Sabanci University, a MSc in Molecular and Cellular Biology and a PhD in Biochemistry from the University of Heidelberg.

JEFF BREAY

Head Trader

Jeff Breay is a Head Trader at RA Capital Management. His responsibilities include managing the portfolio’s public equity positions, monitoring market, sector, and individual equity dynamics, and maintaining relationships with broker/dealer counterparties. Jeff holds a BA in Economics and Psychology from Georgetown. Prior to joining RA Capital, Jeff worked for over 10 years as an institutional equity sales trader, primarily at KCG Holdings, Inc., where he managed the Boston office.

CHRIS CALIRI

Chief Information Officer

Chris Caliri is the Chief Information Officer at RA Capital Management. Chris’ primary responsibility at RA Capital is to oversee the firm’s information technology program, including operations, development, and security. He holds a Master’s degree in Software Engineering from Brandeis University and a BA in Psychology from Providence College. He worked previously as the Director of Business Systems at Bain Capital Credit, and as a Senior Systems Analyst at eSecLending, LLC.

MICHAEL CALORE

Director of Investor Relations

Michael Calore is the Director of Investor Relations at RA Capital Management. Michael’s primary responsibility at RA Capital is to start and maintain relationships with current and potential investors. He was previously a marketing manager at Brighton House Associates, assisting with fundraising campaigns for a diverse group of investment managers, including private equity, venture capital, real estate, and hedge funds. He holds a BS in Finance from Providence College.

TESS CAMERON

Principal

Tess Cameron is a Principal at RA Capital Management. Tess’s primary responsibility is to partner with our portfolio companies as a strategic finance advisor. Tess comes to RA from Foghorn Therapeutics, where she was Head of Finance. Prior to Foghorn, Tess held finance leadership roles at Wave Life Sciences, where she was responsible for FP&A and corporate finance, and Biogen, where she was the finance lead for the CMO and the neurodegeneration portfolio. Prior to joining biotech/pharma, she was a specialist in the corporate finance team at McKinsey &Co, focused on corporate transactions. Tess has a BA with a double major in Economics and Peace & Conflict studies from the University of Toronto, Canada.

PARKER CASSIDY

Principal

Parker Cassidy is a Principal on the Investment Team at RA Capital Management. Parker works on both public and private investments, with a focus on diagnostics. He has a BS in Mechanical Engineering from Boston University and an MBA from Darden Graduate School of Business Administration from the University of Virginia. Prior to RA, Parker was at Farcast Biosciences where he served as the Chief Commercial Officer and most recently as the Head of Strategy and Business Development. Prior to Farcast Biosciences, Parker held various leadership roles of increasing responsibility at both Becton Dickinson and Serologicals.

ANA CASTRO

Research Assistant

Ana is a Research Assistant at RA Capital Management. Ana’s primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Ana’s previous experience includes Research Assistant positions at Massachusetts Eye and Ear Hospital, the Lupus Clinic/Renal Department at the BU Medical Center, and Harvard University Department of Molecular and Cellular Biology. Ana holds an MPH in Epidemiology and Biostatistics from Boston University School of Public Health and a BA in Neuroscience from Boston University.

HARVEY CHAN

Controller

Harvey is a Controller at RA Capital Management. Harvey’s primary responsibility is to oversee all accounting related activities for the firm. Harvey most recently served as Assistant Controller at Charles River Ventures. His prior posts include Fund Accountant at Nautic Partners and HLM Venture Partners. Harvey holds an MS in Finance from Bentley University McCallum Graduate School of Business and a BS in Corporate Finance and Accounting from Bentley University.

JESSE CHEN, PhD

Entrepreneur in Residence

Jesse Chen is an EIR at RA Capital. In this role he works closely with RA’s Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Jesse has more than a decade of discovery research and management experience, from early discovery through preclinical development. Prior to joining RA, Jesse was Senior Director of Discovery at Kymera Therapeutics. As the first and founding member of Kymera’s scientific team, Jesse was responsible for building the company’s industry-leading targeted protein degradation platform and pipeline, and he helped secure the company’s Series A and B financings as well as a partnership with Vertex. Jesse also held research leadership roles at Moderna Therapeutics and Millennium Pharmaceuticals, where he was responsible for developing novel platforms and leading discovery programs. Jesse earned his Ph.D. in Biological Chemistry from MIT and was a Harvard Origins Research Fellow.

LORENA CHEN, CPA

Fund Controller

Lorena Chen is a Fund Controller at RA Capital Management. Lorena's primary responsibility is to oversee all accounting related activities for the firm. She has spent the last five years as a Senior Finance Associate at Great Hill Partners. Prior to GHP, Lorena served as an Assurance Senior at EY. Lorena has dual degrees from Beijing Foreign Studies University: a Bachelor of Business Administration in Accounting and a Bachelor of Arts in English Literature. She also has a Master's in Accounting from Boston College and is a CPA.

SAMUEL CHOWDHURY

Software Developer

Samuel Chowdhury is a Software Developer at RA Capital Management. Sam’s primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. He holds a BS in Computer Engineering and a Minor in Mathematics from Northeastern University.

LAURA CLOSE

Executive Assistant

Laura is an Executive Assistant at RA Capital Management. Laura’s primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the TechAtlas division. Laura has a BS in Human Services; Clinical Concentration and a Minor in Disabilities Studies from the University of Delaware. Laura previously worked at WinterWyman where she served as a Senior Associate.

ERIN CLUTTER

Head of Graphics

Erin Clutter is the Head of Graphics at RA Capital Management. Erin’s primary responsibilities at RA Capital are to manage the design and creation of all internal and external documents and resources for the company, including competitive landscapes of drugs and medical devices for disease indications and capabilities, set brand standards, and oversee internal and external marketing efforts. Erin holds a Bachelor of Fine Arts degree from the Massachusetts College of Art & Design. She worked previously in desktop publishing and as a freelance designer.

MEREDITH COLLINS

Research Assistant

Meredith is a Research Assistant at RA Capital Management. Meredith’s primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Meredith’s previous experience includes Medical Education Researcher and Medical Scribe positions at BMC Global Inc. and Longwood Pediatrics, respectively. Meredith holds a BS in Biology: Pre-Med from the University of North Carolina at Charlotte.

MARY PAT CONNOLLY

Investment Research Coordinator

Mary Pat Connolly is an Investment Research Coordinator at RA Capital Management. Mary Pat’s primary responsibilities at RA Capital are to coordinate various projects across the company and oversee their initiation, planning, and execution. Mary Pat is a PMI-certified Project Management Professional (PMP) and holds a BA in Chemistry from Holy Cross, where she studied biodiesel fuel analysis.

ANDREW COSTENOBLE

Software Developer

Andrew is a Software Developer at RA Capital Management. Andrew’s primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. He holds a BS in Computer Science from Northeastern University.

THOMAS CULMAN

Senior Research Assistant

Thomas Culman is a Senior Research Assistant at RA Capital Management. Tom’s primary responsibility at RA Capital is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Tom holds a BS in Health Sciences with a minor in Journalism from Northeastern University. He worked previously as a Patient Coordinator at Massachusetts General Hospital.

NATE DAVIS

Associate

Nate Davis is an Associate with the TechAtlas division of RA Capital Management. Nate’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Nate has a BS in Biological Sciences from University of Vermont. Nate previously worked as an Investment Analyst at Wolfram Ventures.

MAX DENIES, PhD

Associate

Max DeNies is an Associate with the TechAtlas division of RA Capital Management. Max’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Max has a BS in Biology from the State University of New York at Fredonia and a PhD in Cellular and Molecular Biology from the University of Michigan.

MILIND DESHPANDE, PhD

Venture Partner

Milind Deshpande is a Venture Partner at RA Capital, and President & CEO of Nayan Therapeutics, a RA Capital portfolio company. Milind has more than 25 years of leadership and operational experience through all stages of drug discovery and development. He is the co-founder and Chairman of the Board of Directors of Spero Therapeutics, and past President, CEO and member of the Board of Directors of Achillion Pharmaceuticals. Prior to joining Achillion, Milind was Group Leader at Bristol-Myers Squibb for all early stage discovery programs in infectious diseases and neuroscience. He is the co-inventor of first-in-class HCV NS5A inhibitors, which led to the approval of DaklinzaTM, the first marketed drug in its class. Milind has co-authored more than 80 scientific articles, is co-inventor on 30 patents, and is a frequent speaker at international scientific conferences. He received his doctorate in Organic Chemistry from Ohio University, and was a Fellow and Instructor in Department of Medicine, Boston University School of Medicine. Milind attended the residential Executive Program at The Wharton School of Management.

KLIO DiCENZO

Director of Human Resources

Klio DiCenzo is the Director of Human Resources at RA Capital Management. Klio’s primary responsibilities at RA Capital are to oversee talent development, recruiting, people operations, and culture. Klio also partners with portfolio companies to provide guidance and thought leadership and to support the creation of HR procedures and programs. Klio previously worked as Human Capital leader at athenahealth where she helped build and scale their commercial business unit; during her time there she oversaw the hiring of over 300 employees, the implementation of core HR processes and programs, and the organizational design to accommodate athenahealth’s rapid growth. Prior to athenahealth, Klio held various HR leadership positions at PricewaterhouseCoopers within their consulting, audit, and tax practices where she focused on compensation and employee experience. She holds a Master of Arts in Teaching and a BA in Psychology, both from Simmons University.

JOHN DiNAPOLI

Systems Administrator

John DiNapoli is the Systems Administrator at RA Capital Management. John’s primary responsibility at RA Capital is to provide technical assistance and support for issues related to computer systems, the network, and server environments. John holds a BA in Sociology and Criminal Justice from the University of Massachusetts, Amherst. He previously worked as a Help Desk Manager at Toast.

DEREK DiROCCO, PhD

Principal

Derek DiRocco is a Principal on the Investment Team at RA Capital Management. Derek works on both public and private investments and serves as a Board Director for 89Bio, Ltd. Previously, Derek covered solid tumor oncology landscapes. Derek holds a BA in Biology from Holy Cross College and a PhD in Pharmacology from the University of Washington. He conducted his postdoctoral research at Brigham and Women’s Hospital/Harvard Medical School, where he researched the role of the Wnt signaling pathway in mouse models of kidney disease, and was part of a team that discovered a stem cell subtype responsible for solid organ fibrosis.

BRIANA DUNN, PhD

Senior Associate

Briana Dunn is a Senior Associate within the TechAtlas division of RA Capital Management. Briana’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Briana holds a BS in Chemical Engineering from Cornell University, and a PhD in Chemical Engineering from Stanford University. Her graduate research focused on engineering polyketide synthases for the production of novel polyketide therapeutics. Briana previously worked as a postdoctoral associate at MIT, where she investigated bacteriophages as biological building blocks for the creation of hybrid organic-inorganic catalytic systems.

RAMIN FARZANEH-FAR, MD

Venture Partner

Ramin Farzaneh-Far is a Venture Partner at RA Capital where he works closely with RA’s Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs. He was Chief Medical Officer of Ra Pharmaceuticals from 2016 until it was acquired by UCB in 2020. Ramin is an experienced clinical trialist and previously led global clinical development programs at Akebia Therapeutics and Gilead Sciences. A trained cardiologist, he has held academic faculty positions at the University of California, San Francisco (UCSF) and the University of Texas Southwestern Medical Center. Ramin completed his internal medicine residency at Brigham & Women’s Hospital in Boston and trained in cardiovascular medicine at UCSF. He holds BA and MA degrees in immunology from the University of Cambridge, an MD from University College London, and an MAS in clinical research from UCSF.

DANIELLE FELDMAN, PhD

Entrepreneur in Residence

Danielle Feldman is an Entrepreneur-in-Residence at RAVentures and was a Co-Founder and Associate Director of Corporate Development at AthenenTx, a neuro-focused RA-funded NewCo that spun out in 2019. She has a PhD in Neuroscience from MIT and prior to her time at Athenen, she worked as an Associate on the Tech Atlas team at RA Capital, covering Neuro, GI, and Orphan indications.

STEFANIE FELDMANN

Senior Executive Assistant and Senior Operations Manager

Stefanie Feldmann is the Senior Executive Assistant to the Co-founders and Senior Operations Manager. Stef joins us from SV Health Investors where she oversaw multiple key operations initiatives as an Administrative Manager. Prior to SV, she has held numerous administrative and operations positions at Royal Bank of Canada, inviCRO, and Veritas Tutors. Stef earned her M.A. in Linguistics and Musicology from Freie Universitat Berlin, Germany.

MATT FERESTEN

Research + Technology Manager

Matthew Feresten is a Research and Technology Manager at RA Capital Management. Matt’s primary responsibilities at RA Capital are to gather team input to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities, and to provide software training and coordinate with outside technology vendors. He holds a BS in Biology from the College of William and Mary, where he studied the impact of ecological fragmentation on the prevalence of ticks and their bacterial pathogens.

CAT FLAHERTY

Executive Assistant

Cat is an Executive Assistant at RA Capital Management. Cat’s primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the Investment Division. Cat previously held posts as an Executive Assistant at Draper Richards Kaplan Foundation and Bain Capital. She has a BA in Liberal Studies from Endicott College and a Certificate in Interior Design from Parsons School of Design.

CANDICE GALVEZ

Executive Assistant

Candice Galvez is an Executive Assistant at RA Capital Management. Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. Candice has a BS in Mass Communications from Emerson College. Candice previously worked as the Director of Executive Office and Administration at Flywire. Prior to Flywire, she worked as an Executive/Personal Assistant at Spark Capital.

MICHAEL GILLESPIE, MD

Associate

Michael Gillespie is an Associate within the TechAtlas division of RA Capital Management. Michael’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Michael's previous experience includes venture development at Health Wildcatters Seed Accelerator and product development in various roles at the Institute for Environmental and Exercise Medicine and as an Aerospace Medicine Clerk at NASA. Michael holds a BS in Exercise Science from Brigham Young University and an MD from the University of Texas Southwestern School of Medicine.

ERNESTO GONZALEZ

Senior Business Systems Analyst

Ernesto Gonzalez is a Senior Business Systems Analyst at RA Capital. Ernesto’s primary responsibility at RA Capital is to coordinate various technology related initiatives across the company and oversee their initiation, planning, and execution. He previously held roles as VP Product Manager - Data Services at Charles River Development (a State Street Company) and Senior Business Analyst in Capital Markets at Bain Capital Credit and State Street Global Exchange, DataGX. He holds a BA in History from University of Massachusetts, Amherst and a Master's of Urban Affairs from Boston University.

EMILY GREEN

Senior Graphic Designer

Emily Green is a Senior Graphic Designer at RA Capital Management. Emily’s primary responsibility at RA Capital is to create graphics, charts, and other visuals for competitive landscapes of drugs and medical devices for disease indications and capabilities. In addition, she is responsible for overseeing content management for the RA Capital website, and designing visual elements for other internal and external communications. Emily holds a BS in Graphic Design from James Madison University.

JAMES C. GREENWOOD

Advisor

Jim Greenwood is an Advisor at RA Capital. Prior to joining RA, Jim was the President and CEO of the Biotechnology Innovation Organization (BIO), the world’s largest biotechnology trade association, where he worked on international, federal, and state policies aimed at helping innovative biotech companies succeed. Prior to his 15-year tenure at BIO, Jim served for 12 years in the United States House of Representatives and was appointed Chair of the Energy and Commerce Committee Subcommittee on Oversight and Investigations; in this role he led several high-profile investigations into corporate malfeasance, cyber and bio-terror threats, the national opioid crisis, as well as numerous others. Previously he served for 12 years in the Pennsylvania State House and Senate. Jim earned his BA in Sociology from Dickinson College.

MATTHEW HAMMOND, PhD

Principal

Matthew Hammond is a Principal on the Investment Team at RA Capital Management. Matthew works on both public and private healthcare companies and serves as a Director on the Board of Cerebral Therapeutics. Matthew holds a BS in Environmental Health Science from the University of Georgia and both a PhD in Biomedical Science and an MBA with a concentration in Finance from the University of Connecticut. His graduate research investigated innate immune responses after intracerebral hemorrhage.

NIKKI HECHT

Human Resources Generalist

Nikki is a Human Resources Generalist at RA Capital Management. Nikki’s primary responsibilities at RA Capital are to assist in full cycle talent management and recruiting. Nikki previously worked as a Human Resources Manager, Office Manager and Executive Assistant at the State Services Organization in Washington, DC. She has also held roles in Marketing and Client Services at West, Lane & Schlager and CBRE respectively. Nikki has a BA in Communication Studies from Christopher Newport University.

BARBARA HERBST

Deputy Chief Compliance Officer

Barbara Herbst is the Deputy Chief Compliance Officer at RA Capital Management. She is involved with the firm’s back office and operations, including finance, audit, compliance, partner relationships, and business continuity and policies. Barbara holds a BS in Business Administration with a concentration in Finance from Boston University and has 11 years of experience in operations, compliance, and trading.

BENJAMIN HICKS

Compliance Officer

Benjamin Hicks is a Compliance Officer at RA Capital Management. Benjamin’s primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. He holds a BA in Neuroscience with a minor in Molecular and Cellular Biology from Colorado College. Benjamin previously worked in clinical research as a Site Operations Associate for a contracted research organization specializing in Ophthalmology.

NATHANIEL BROOKS HORWITZ

Venture Associate

Nathaniel is a Venture Associate within the Venture team at RA Capital Management. Nathaniel’s primary responsibility at RA Capital is to identify compelling opportunities to help facilitate new company creation or investments in emerging seed-stage companies. He previously served as the Founder & CEO of Nivien Therapeutics. Nathaniel graduated from Harvard University with a BA in Molecular and Cellular Biology.

MARIAGRACE HOULLAHAN

Executive Assistant

Mariagrace Houllahan is an Executive Assistant at RA Capital Management. Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. Mariagrace has a BS in Sociology from Suffolk University. Mariagrace previously worked as an Executive Assistant at MPM Capital. Prior to MPM, she worked as an Executive Assistant at Charles River Ventures.

JAMIE KASUBOSKI, PhD

Venture Senior Associate

Jamie is a Venture Senior Associate at RA Capital Management. Jamie’s primary responsibility at RA Capital is to identify compelling assets to help facilitate new company creation or investments in emerging seed-stage companies. Jamie holds a BS in Biology with a minor in Chemistry from Hillsdale College and a PhD in Molecular and Cellular Biology from the University of Notre Dame. Jamie previously focused on early stage Biotech investing as a Director at Boehringer Ingelheim Venture Fund and served as a Board Director of both Tilos Therapeutics (acquired Merck & Co.) and Rewind Therapeutics. Jamie also spent four years as a Research Fellow in Pfizer’s Neuroscience Research Unit and three years building experimental research microscopes in the Waitt’s Biophotonics Center at the Salk Institute for Biological Studies.

EMILY KELTY

Business Analytics Associate

Emily Kelty is a Business Analytics Associate at RA Capital Management. Emily's primary responsibilities at RA Capital are to support and build new research capabilities. Emily holds a BS in Allied Health Sciences with a Minor in Biology from the University of Connecticut. She worked previously in Ireland within the Healthcare Division of Cpl Recruitment and as a Contract Assistant for the Health and Social Care Professionals Council.

NATALIE KOSTICH

Senior Program Manager

Natalie is a Senior Program Manager at RA Capital working closely with the firm’s Managing Partner, Peter Kolchinsky, on a wide array of internal and external initiatives. Prior to RA, Natalie served as MA State Operations Director for Mike Bloomberg 2020 and Campaign Manager for E. Denise Simmons, Cambridge City Council. Prior to her political campaign experience, she led expansion efforts as Consultant, Director of Partnerships for child-focused rideshare start-up, Zemcar. Natalie spent the first 13+ years of her career at EF Education First in varying leadership roles in sales and operations both domestically and overseas in Switzerland and the Russian Federation. Natalie holds an MPA and a Certificate in Management, Leadership, and Decision Sciences from the Harvard Kennedy School, as well as a BA in Sociology and Spanish and a Minor in Russian from College of the Holy Cross.

TYLER KOWALSKI

Senior Graphic Designer

Tyler Kowalski is a Senior Graphic Designer at RA Capital Management. Tyler’s primary responsibility at RA Capital is to create graphics, charts, and other visuals for competitive landscapes of drugs and medical devices for disease indications and capabilities. Tyler holds a BA in Finance from the University of Massachusetts, Amherst. He worked previously as a freelance graphic designer.

VIKRAM SHEEL KUMAR, MD

Venture Partner

Vikram Sheel Kumar is a Venture Partner at RA Capital where he is applying software to develop drugs and new ventures. He is co-founder and CEO of Clear Creek Bio, an RA Capital portfolio company. Vikram studied engineering at the Indian Institute of Technology, Delhi before earning a BS in Operations Research with honors from Columbia University. He holds an MD magna cum laude from Harvard-MIT, Program in Health Sciences and Technology, where he was a Paul and Daisy Soros Fellow. He was named an MIT Technology Review 100 innovators under 35 for his MIT Media Lab social enterprise, Dimagi, that has impacted millions with its mobile data collection platform. Vikram trained in clinical pathology at the Brigham and Women’s Hospital where he was chief resident.

CHRISTY KUO, PhD

Associate

Christy is an Associate with the TechAtlas division of RA Capital Management. Christy’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Prior to RA, Christy was a Senior Scientist in Oncology Target Discovery at Pfizer. She was also an Entrepreneurial Fellow at VentureLabs for Flagship Pioneering. Christy has an MS in Immunology from National Taiwan University, a PhD in Immunology and Microbial Pathogenesis from Cornell University, and a mini-MBA in BioPharma Innovation from Rutgers Business School.

ALYSSA LARSON, PhD

Senior Associate

Alyssa Larson is an Senior Associate with the Orphan Disease Team within the TechAtlas division of RA Capital Management. Alyssa’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Alyssa holds a BS in Biochemistry from the University of California, Santa Barbara, and a PhD in Biochemistry from MIT. Her graduate research investigated inhibitors of influenza virus and characterizing hydrophobic polycationic antimicrobial surfaces. Alyssa previously worked as a Senior Scientist at Eagle Pharmaceuticals.

CHRISTINA LILLIEHOOK, PhD

Senior Science Writer

Christina is a Senior Science Writer at RA Capital Management. Christina’s primary responsibility is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Christina’s previous experience includes Stem Cell Program Manager at the Broad Institute and Deputy Editor at Cell Stem Cell. Christina holds a PhD in Neuroscience from the Ichan School of Medicine at Mount Sinai and a BS in Biochemistry from Stockholm University.

JON LUNDT, PhD

Associate

Jon Lundt is an Associate within the TechAtlas division of RA Capital Management. Jon's primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Jon has a PhD in Biomedical Engineering from the University of Michigan, an MS in Mechanical Engineering from Boston University, and a BS in Physics from the University of Washington.

SRI MAHENDRA

Senior Software Engineer

Sri Mahendra is a Senior Software Engineer at RA Capital Management. Sri’s primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. He holds a Bachelor’s degree in Electronics and Communications from Anna University, and a Master’s degree in Computer Science from Northeastern University. He previously worked as a Software Engineer for several companies, including Autodesk, the Advisory Board Company, and Maveric Systems.

KATIE MAHER, PhD

Senior Compliance Officer

Katie Maher is a Senior Compliance Officer at RA Capital Management. Katie’s primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. She holds a BS in Biology from Pennsylvania State University and a PhD in Molecular and Cellular Biology from the University of Massachusetts, Amherst. Her doctoral work integrated molecular and genetic strategies to study the mechanism by which dopamine modulates neuronal activity in both individual neurons and neural circuits.

IRA MALE, PhD

Associate

Ira is an Associate with the TechAtlas division of RA Capital Management. Ira’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Ira has a BS in Biology with a minor in Chemistry from Worcester State College and a PhD in Molecular and Cellular Biology from the University of Massachusetts, Amherst.

DAN MARKS, PhD

Venture Associate

Dan Marks is a Venture Associate within the Venture team at RA Capital Management. Dan’s primary responsibility at RA Capital is to identify compelling opportunities to help facilitate new company creation or investments in emerging seed-stage companies.. Dan holds a BS with Honors in Biology from Yale University and a PhD in Cancer Biology from the Gerstner Sloan Kettering School of Biomedical Sciences. His graduate research focused on identifying novel targets for disrupting the cell cycle in cancer cells.

JAMES McARTHUR, PhD

Venture Partner

James McArthur is a Venture Partner at RA Capital Management. James was most recently the founder, Chief Executive Officer, and served as a Board Director for Imara, a public company developing therapies for sickle cell disease and β-thallasemia. He was also the co-founder and President of Research and Development of Cydan, a rare disease accelerator. James has over 25 years of industry experience in creating and building biotechnology companies including experience as a co-founder of the lysosomal storage diseases company Vtesse acquired by Sucampo/Malinkrodt, co-founder of the clinical stage neuroendocrine company Tiburio, Board Director of the ocular gene therapy company Nightstar acquired by Biogen, and as founding Chief Scientific Officer of the rheumatology therapy company Synovex/Adheron acquired by Roche. Prior to these companies, James held senior research leadership roles in the gene and stem cell therapy companies Cell Genesys, Phylogix, and Somatix Therapy. James was an entrepreneur in residence at HealthCare Ventures, an advisor to Kurma Ventures, and is on the Scientific Advisory Board and Board of Directors of the Friedreich’s Ataxia Research Alliance (FARA), a patient advocacy group. James was a post-doctoral fellow at Massachusetts Institute of Technology and University of California, Berkeley. He worked with Dr. David Raulet and Nobel Laureate Dr. James Allison before which he received a PhD in Molecular Oncology and BSc in Biochemistry from McGill University in Montreal.

BRITTANY McKINNON

Executive Assistant and Recruiting Coordinator

Brittany McKinnon is an Executive Assistant and Recruiting Coordinator at RA Capital Management. Brittany’s primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the Operations division as well as assist in all of the firm’s recruiting efforts. Brittany previously worked as a Delivery Specialist at Randstad Technologies. She holds a BA in Communications from Bryant University.

SARA McMENIMEN

Senior Executive Assistant

Sara is a Senior Executive Assistant. Her primary responsibilities are to support our Operations Team by coordinating management agendas, calendars, and external events. Sara has a BA in Media and Society, Minor in English from Hobart and William Smith College. Sara previously worked as an Executive Assistant at Battery Ventures. Prior to Battery, she held administrative leadership positions at CBRE.

DAVID MIGL, PhD

Associate

David is an Associate within the TechAtlas division of RA Capital Management. David’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. David holds a PhD from Harvard University in Biophysics and a BS in Molecular Biology from Texas A&M University.

CRISTINA MONTERO, PhD

Associate Director

Cristina Montero is an Associate Director within the TechAtlas division of RA Capital Management. Cristina’s primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Prior to this role, Cristina mapped a number of competitive landscapes, including respiratory, allergic, and infectious disease conditions. Cristina holds a BA in Molecular Biology with a minor in Business from Washington University in St. Louis, and a PhD in Microbiology and Molecular Genetics from Harvard University. Her doctoral research focused on bacteriophage-mediated regulation of bacterial transcription.

KATE MOREAU, PhD

Associate Director

Kate Moreau is an Associate Director within the TechAtlas division of RA Capital Management. Kate’s primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Prior to this role, Kate worked with the Venture team evaluating early stage investment opportunities and mapped a number of competitive landscapes, including ophthalmology, lower GI, and non-viral liver disease. Kate holds a BA in Molecular Biology and Biochemistry from Rutgers University, and a PhD in Biochemistry from MIT. Her doctoral research investigated the folding and aggregation of gamma-crystallins associated with cataract formation.

CHRIS MORRISON

Editor

Chris Morrison is an Editor at RA Capital Management. Chris’s primary responsibility at RA Capital is to cover the biotech and pharma industry. Chris has a BS in Neurobiology and Behavior from Cornell University and a MA in Journalism from New York University. Prior to RA, Chris was at Elsevier Business Intelligence, where he served as Writer/Editor and eventually became the Editor in Chief for Biopharmaceuticals and Consumer Products.

DAYNA MUCCI

Legal Associate

Dayna Mucci is a Legal Associate at RA Capital Management. Dayna’s primary responsibilities are to advise on regulatory and legal matters. Dayna holds a BA in International Relations and Economics from Boston University and a JD from Boston University School of Law. Dayna is admitted to practice law in the Commonwealth of Massachusetts.

THIEN NGUYEN, PhD

Associate

Thien is an Associate with the TechAtlas division of RA Capital Management. Thein’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Thien has a BS in Biology from the University of North Carolina at Chapel Hill and a PhD in Pharmacology and Physiology from Georgetown University Medical Center- NIH Graduate Partnership Program.

NICOLE NORTON

Office Manager

Nicole is an Office Manager at RA Capital Management. Nicole’s primary responsibilities are to coordinate office activities and operations. Nicole previously worked as a Business Systems Technician at Jacobs Engineering Group. She has also held roles in Marketing at RE/MAX, LLC and Aimco Properties. She holds a BS in Business Administration from Wayne State University.

TIMOTHY NOYES, MBA

Venture Partner

Timothy Noyes is Venture Partner at RA Capital and CEO of Arcuate Therapeutics. In this role he works closely with RA’s Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Timothy is a veteran biotech leader with deep experience in growing companies and bringing innovative therapies to market. Prior to joining RA Capital and Arcuate Therapeutics, Tim was President and CEO of Proteon Therapeutics, a company focused on developing novel therapeutics to improve the lives of patients with kidney and vascular diseases. Tim was hired as the fourth employee at Proteon and built a team that brought an innovative biologic for blood vessel remodeling from pre-clinical through two Phase 3 clinical trials. Before joining Proteon, Tim was the COO of Trine Pharmaceuticals and he held several management positions with GelTex Pharmaceuticals prior to its acquisition by Genzyme. Tim was responsible for building the commercial team at GelTex and launching Renagel, a novel treatment for patients with kidney failure that grew to a $1B franchise . After the acquisition, Tim was named President of Genzyme’s Renal Division and GelTex Pharmaceuticals. Tim began his career at Merck & Co., serving in multiple commercial roles in its cardiovascular, gastrointestinal, and managed care divisions. Tim received his A.B. from Harvard College and an M.B.A. from Harvard Business School.

JONATHAN PRITZ, PhD

Senior Associate

Jonathan Pritz is a Senior Associate with the Oncology Team within the TechAtlas division of RA Capital Management. Jonathan’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Jonathan holds a BS in Microbiology and Cell Science from the University of Florida, and a PhD in Biological Chemistry and Molecular Pharmacology from Harvard University. His graduate research investigated chemical activators of cell death in cancer.

FABIO PUCCI, PhD

Associate

Fabio is an Associate within the TechAtlas division of RA Capital Management. Fabio’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Fabio holds a BSc in Biotechnology from the Universita Federico II, a PhD in Cell and Molecular Biology from the University of Edinburgh, and an MBA from the London Business School. Fabio previously worked as an MBA Associate at F-prime Capital in the UK and Versant Ventures in Canada.

SARAH REED

General Counsel

Sarah Reed is the General Counsel at RA Capital Management. Sarah joined our team from MPM Capital where she served as the COO & General Counsel. Prior to MPM, Sarah was the General Counsel for Charles River Ventures and before that, at Palomar Medical Technologies. Sarah began her legal career with Foley, Hoag, & Eliot LLP. Sarah earned her BA from Harvard College in East Asian Studies and her JD from Harvard Law School. Sarah is the only lawyer to have received the NVCA’s Outstanding Service Award, for her leadership role in conceiving of and spearheading the NVCA Model Legal Documents. Sarah teaches a course at Harvard Law School on venture capital fund formation.

JACQUELINE RHUDA

Research Assistant

Jacqueline a Research Assistant at RA Capital Management. Jacqueline’s primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Prior to RA, she spent two years as a Research Intern and Teaching Assistant at Johns Hopkins University, Department of Biology and the Department of Chemistry. Jacqueline has a BS in Molecular and Cellular Biology from John Hopkins University.

ROOZBEH RIAHI

Associate

Roozbeh Riahi is an Associate within the TechAtlas division of RA Capital Management. Roozbeh’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Roozbeh has a BS in Neuroscience from UCLA.

ALONSO RICARDO, PhD

Entrepreneur in Residence

Alonso Ricardo is an Entrepreneur in Residence at RA Capital, where he works closely with RA’s Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs. Prior to joining RA Capital, Alonso was Chief Technology and Innovation Officer at Ra Pharmaceuticals until it was acquired by UCB in 2020. At Ra Pharma, Alonso held various leadership roles where he initiated and led the scientific efforts for the company in multiple preclinical and clinical programs; working in a wide set of therapeutic areas and using different molecular modalities. In this role, he gained broad expertise across all phases of drug discovery, early development, and clinical research. Alonso completed his Ph.D. in Chemistry at the University of Florida and his post-doctoral work as a Howard Hughes Medical Institute Fellow at Harvard University and the Massachusetts General Hospital. Alonso was also a chemistry professor at the Universidad de los Andes in Colombia.

ERIC ROSE, MAcc, CFA, CPA

Chief Compliance Officer

Eric is the Chief Compliance Officer at RA Capital Management. Eric previously served as Director, Chief Risk and Compliance Officer, Americas at Aberdeen Asset Management. Prior to joining Aberdeen, Eric worked as a Compliance Examiner at the US Securities and Exchange Commission. Eric holds a MAcc from Bentley University and a BS in Finance from George Mason University.

ADAM ROSENBERG

Venture Partner

Adam Rosenberg is a Venture Partner at RA Capital Management. Adam was most recently President, CEO and member of the Board of Directors of Rodin Therapeutics until its acquisition by Alkermes in 2019. Adam has 20+ years of industry experience in building healthcare and technology companies, including as CEO and co-founder of Link Medicine, a company focused on developing disease-modifying neurodegenerative therapies and as CEO and co-founder of Teleos Therapeutics, an innovative neuroscience drug discovery platform company. Adam has led and advised companies in diverse areas such as digital health, materials and diagnostics, and has served as Director on the board of multiple venture-backed companies. Adam was also an advisor and investor in “A Late Quartet”, an entrepreneurial feature film centered on a cellist diagnosed with Parkinson’s disease, starring Philip Seymour Hoffman, Catherine Keener and Christopher Walken. Adam received his JD from the University of Virginia School of Law, and his BA from Whittier College.

J. MICHAEL RYAN, MD

Entrepreneur in Residence

Michael Ryan is an EIR at RA Capital. He most recently served as Chief Medical Officer for Rodin Therapeutics, where he led all clinical development activities from first-in-human through patient studies until the acquisition by Alkermes. He has held multiple senior level clinical development positions including Chief Medical Officer at Asceneuron SA and Neurodegeneration Therapeutic Area Head at Novartis. Michael received his undergraduate degree at Georgetown University and his medical degree at the Medical University of South Carolina. He completed an internship in Internal Medicine and residency in Psychiatry at the University of Utah Health Sciences Center. Dr. Ryan was also a fellow in Geriatric Psychiatry and Neuropsychiatry at Dartmouth-Hitchcock Medical Center. He was a faculty member at the University of Rochester School of Medicine prior to joining Merck Research Laboratories in 2004.

JESSICA SAGERS, PhD

Head of Engagement

As Head of Engagement, Jessica Sagers directs a concerted effort at RA Capital Management to analyze, design, and shape internal and external narratives. She works with RA’s newcos to develop optimal pitch decks and public messaging, develops educational materials for the firm’s internal and external business courses, authors articles, and presents at conferences on concepts such as the biotechnology social contract that she and colleagues have written on. She holds a BA in Linguistics from Brigham Young University and a PhD in auditory neuroscience from the Division of Medical Sciences at Harvard University. Her graduate research investigated novel small molecule approaches to treating vestibular schwannoma and neurofibromatosis type 2.

MICHAEL SAULNIER, CPA

Senior Controller

Michael is a Senior Controller at RA Capital Management. He is involved in the firm’s back office and operations, including finance, accounting, auditing, taxes, regulatory, and legal. Prior to RA, Michael was a Special Projects Manager at Baupost, LLC. Prior to Baupost, he spent over five years as a Controller at Centerbridge Partners, LP. Michael has also held leadership positions at Citigroup-HedgeFund Services in both Fund Accounting and Product Management before joining Centerbridge. Prior to Citigroup, Michael held various accountant and analyst roles at EY, Morgan Stanley, BBH, and Deloitte. Michael has a BS in Business Administration from Boston University with concentrations in Finance and Accounting. Michael is a CPA.

ZACH SCHEINER, PhD

Principal

Zach Scheiner is a Principal on the Investment Team at RA Capital Management. Zach works on both public and private investments and serves as a Board Director for Nkarta Therapeutics, Inc., and Sydnexis, Inc. Previously, Zach covered the neurology, ophthalmology, and dermatology landscapes. Zach holds a BS in Molecular Biophysics and Biochemistry from Yale University, and a PhD in Neurobiology and Behavior from the University of Washington. His doctoral research focused on the regulation of the ERK/MAPK pathway by adenylyl cyclases during long-term memory formation and sensitization to drugs of abuse. Zach previously worked as a Science Officer at the California Institute for Regenerative Medicine.

ERICH SCHELLER, PhD

Director of TechAtlas

Erich Scheller is the Director of the TechAtlas division of RA Capital Management. Erich’s primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Prior to this role, Erich mapped a number of competitive landscapes including lung cancer, obesity, and chronic kidney disease. Erich holds a BA in English Literature and Language from Harvard University and a PhD in Microbiology from the University of North Carolina, Chapel Hill. His graduate research investigated the role of fimbria in Bordetella adherence and virulence.

BRETT SCHELLER

Compliance Associate

Brett Scheller is a Compliance Associate at RA Capital Management. Brett’s primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. Brett holds a BS from Washington University, St. Louis and a JD from Duquesne University School of Law and is admitted to practice law in PA. Brett previously served as a Clerk for the Washington County Court of Common Pleas in PA.

EMILIE SCHLEER

Investor Relations Manager

Emilie Schleer is the Investor Relations Manager with the Operations Team at RA Capital Management. Emilie’s primary responsibility at RA Capital is to manage current and potential investor relationships. Prior to joining RA Capital, Emilie was a Vice President of Investor Relations at THL Credit. Emilie has previously held similar roles at FLAG Capital Management and Bain Capital. She holds a BS in Finance from Elon University and an MBA from Babson College.

JAMES SCHNEIDER

Associate General Counsel

James Schneider is the Associate General Counsel at RA Capital Management. James’ primary responsibilities are to advise RA Capital on public and private investments, coordinate with portfolio companies regarding deal structures and terms, and provide counsel and oversight on regulatory matters. James holds a BS in Journalism from Boston University and a JD from Boston College Law School. He previously worked as a corporate attorney at Foley Hoag LLP and Cooley LLP. James is admitted to practice law in the Commonwealth of Massachusetts.

ANDREW SENESI, PhD

Associate, Global Innovation

Andrew Senesi is an Associate in Global Innovation within the TechAtlas division of RA Capital Management. Andrew’s primary responsibility at RA Capital is to identify and assess orthogonal technologies that intersect with the healthcare industry. Andrew holds a PhD in Chemistry from Northwestern University, where he focused on the development of DNA scaffold-based nanoparticle superlattices with novel emergent properties. His postdoctoral work at Argonne National Laboratories involved characterization of nanomaterials using X-ray scattering technologies. Andrew worked previously as an associate at the Chicago Innovation Exchange, a University of Chicago-focused incubator with an associated VC fund.

GERALD SEWACK, PhD

Director of Scientific Operations

Gerald is the Director of Scientific Operations at RA Capital Management. Gerald’s primary responsibility is to leverage RA Capital’s TechAtlas platform to identify differentiated opportunities for new venture formation. Gerald holds a PhD in Molecular and Cellular Biology from Harvard Medical School. His research investigated chromatin structure and transcription factor binding. He worked previously at Global Prior Art, an intellectual property analysis firm, as a Partner and the Director of the Life Sciences Division.

NADIM SHOHDY, PhD

Entrepreneur in Residence

Nadim Shohdy is an EIR at RA Capital. In this role he works closely with the RA Ventures team to evaluate and incubate early stage therapeutic programs. Nadim has 11+ years’ experience in commercializingdrug discovery across diverse indications and modalities. Prior to joining RA, Nadim was at NYU School of Medicine as Associate Dean of Therapeutics Alliances, a drug discovery accelerator that de-risks academic research towards partnerships with biopharma, investors, and nonprofits. Under his leadership, Therapeutics Alliances advanced 40+ projects, including 11 projects partnered with biopharma or new startups such as Repare Therapeutics and GliXogen Therapeutics. Prior to co-founding Therapeutics Alliances, Nadim worked in NYU’s Industrial Liaison technology transfer group, and was a Research Analyst at the International AIDS Vaccine Initiative. Nadim completed his BS in Biology at Stony Brook University, received his PhD with Distinction in Microbiology at Columbia University, and was an NRSA Postdoctoral Fellow studying the cell biology of HCV in the laboratory of Nobel Prize winner Charles M. Rice at the Rockefeller University.

JAKE SIMSON, PhD

Principal

Jake Simson is a Principal on the Investment Team at RA Capital Management. Jake works on both public and private investments and serves as a Board Director for Xenikos, B.V. Previously, Jake covered solid tumor oncology landscapes. Jake holds a BS in Materials Science and Engineering from MIT and a PhD in Biomedical Engineering from Johns Hopkins University. In his doctoral research, he investigated clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels.

RISA STACK, Ph.D.

Venture Partner

Risa is a Venture Partner at RA Capital. She has played a significant role in the early operations, financing, and development of over 25 companies. Companies include: Veracyte (NASDAQ:VCYT), Foundation Medicine (NASDAQ:FMI) Trius (NASDAQ:TSRX, sold to Cubist), Pacific Biosciences (NASDAQ:PACB), Corthera (acquired by Novartis), Quantum Health (acquired), and Menlo Microsystems. Most recently Risa created and led the GE Ventures New Business Creation team which founded seven new businesses across multiple industries including healthcare, aviation, and energy. Prior to GE Ventures Risa was a partner at Kleiner Perkins Caufield & Byers where she founded and developed therapeutics, tools, and molecular diagnostics companies. She began her investing career at J.P. Morgan Partners where she sponsored venture and growth investments in healthcare companies and supported international healthcare investing. Before joining the venture capital industry, Risa worked as a derivative specialist on the Chicago Board of Trade, where she traded futures and options on government securities. Risa holds a B.S. in Genetics and Development with distinction from the University of Illinois, a Ph.D. in Immunology from the University of Chicago, and was a member of the second class of Kauffman Fellows.

MONICA STANCIU, PhD

Senior Associate

Monica Stanciu is a Senior Associate within the TechAtlas division of RA Capital Management. Monica’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Monica holds a BSc in Neuroscience and Pharmacology from the University of Toronto and a PhD in Cancer Biology from MIT. Her graduate research investigated novel epigenetic regulators in glioblastoma. Monica previously worked as a Licensing Manager at Partners HealthCare Innovation.

LAURA STOPPEL, PhD

Analyst

Laura Stoppel is an Analyst on the Investment Team at RA Capital Management. Laura’s primary responsibility at RA Capital is to conduct due diligence on biotechnology companies. Prior to this role, Laura was a Senior Associate on the Oncology, Ophthalmology, and Neurology Teams within the TechAtlas division of RA Capital, where she mapped competitive landscapes of drugs and medical devices for disease indications and capabilities, with a focus on hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders. Laura holds a BA in Biology and Psychology from Harvard University, and a PhD in Neuroscience from MIT. Her graduate research investigated synaptic translation in syndromic autism.

ALEX STRASSER

Junior Associate

Alex is a Junior Associate with the TechAtlas division of RA Capital Management. Alex’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Alex has a BA in Chemistry and a Minor in Religious Studies from Davidson College.

KALEEN SULLIVAN

TechAtlas Project Coordinator

Kaleen Sullivan is a Project Coordinator at RA Capital Management. Kaleen’s primary responsibility is to oversee the initiation, planning, and execution of various projects within the TechAtlas Division. She holds a BBA in Marketing from Loyola University Maryland.

DING SUN

Senior Software Engineer

Ding Sun is a Senior Software Engineer at RA Capital Management. Ding’s primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. He holds a BS in Computer Science from The University of California, San Diego, and worked previously as a Software Engineer at IBM and Fidelity Investments.

LAURA TADVALKAR, PhD

Venture Senior Associate

Laura Tadvalkar is a Venture Senior Associate at RA Capital Management. Laura’s primary responsibility at RA Capital is to identify compelling assets to help facilitate new company creation or investments in emerging seed-stage companies. Laura has a BS in Chemistry from Yale University and a PhD in Chemical Biology from Harvard University. Prior to RA, Laura was a Principal at MP Healthcare Venture Management. Prior to MP, She was a Consultant at Clarion Healthcare.

KATHERINE TERRANOVA

Junior Associate

Katherine Terranova is a Junior Associate within the TechAtlas division of RA Capital Management. Katherine’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Katherine has a as a BA in Mathematics and a Minor in Chemistry from Boston College and a Master of Science in Medical Science from Boston University School of Medicine.

MATTHEW THERKELSEN, PhD

Associate

Matthew is an Associate within the TechAtlas division of RA Capital Management. Matthew’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Matt holds a PhD in Biological Sciences from Purdue University as well as BA in Biochemistry/Molecular Biology (and a Minor in Mathematics) from Hamilton College.

SHAN SHAN WANG, PhD

Associate

Shan Shan is an Associate within the TechAtlas division of RA Capital Management. Shan Shan’s primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Shan Shan holds a PhD in Neuroscience from Harvard University and a BS in Brain and Cognitive Sciences from MIT.

TJ WARWICK

Fund Accountant

TJ is a Fund Accountant at RA Capital Management. His primarily responsibilities are to assist with all finance operations related to the Firm. Prior to RA, TJ was at KPMG where he was a Senior Audit Associate. Prior to KPMG, TJ worked within the AP/Office Admin function with the Boston Red Sox. TJ has a BS in Business Administration with a concentration in Accounting from Northeastern University.

BETHANY WRIGHT

Finance Associate

Bethany is a Finance Associate at RA Capital Management. Her primarily responsibilities are to assist with all finance operations related to the Firm. She previously held posts as an Accounts Receivable Analyst at the MFA Companies and as an Administrative Assistant at the Massachusetts Eye and Ear Infirmary. She holds a BS in Corporate Finance & Accounting from Salem State University.

KAI WU

Chief Financial Officer

Kai Wu is the Chief Financial Officer at RA Capital Management. He is involved in the firm’s back office and operations, including finance, accounting, auditing, taxes, regulatory, and legal. Kai previously served as the CFO/CCO of both Palo Alto Investors and Lucerne Capital Management. He holds a BS in Business Administration from Georgetown University.

Team Members

PETER KOLCHINSKY, PhD

PETER KOLCHINSKY, PhD

RAJEEV SHAH

RAJEEV SHAH

ANDREW LEVIN, MD/PhD

ANDREW LEVIN, MD/PhD

JOSH RESNICK, MD

JOSH RESNICK, MD

RYAN BERRY, PhD

RYAN BERRY, PhD

TESS CAMERON

TESS CAMERON

PARKER CASSIDY

PARKER CASSIDY

MARY PAT CONNOLLY

MARY PAT CONNOLLY

DEREK DiROCCO, PhD

DEREK DiROCCO, PhD

MATTHEW HAMMOND, PhD

MATTHEW HAMMOND, PhD

NATHANIEL BROOKS HORWITZ

NATHANIEL BROOKS HORWITZ

JAMIE KASUBOSKI, PhD

JAMIE KASUBOSKI, PhD

DAN MARKS, PhD

DAN MARKS, PhD

JESSICA SAGERS, PhD

JESSICA SAGERS, PhD

ZACH SCHEINER, PhD

ZACH SCHEINER, PhD

GERALD SEWACK, PhD

GERALD SEWACK, PhD

JAKE SIMSON, PhD

JAKE SIMSON, PhD

LAURA STOPPEL, PhD

LAURA STOPPEL, PhD

LAURA TADVALKAR, PhD

LAURA TADVALKAR, PhD

DANIEL BAHCHELI

DANIEL BAHCHELI

PETER BALOGH

PETER BALOGH

MATT BEVERLY, PhD

MATT BEVERLY, PhD

ASTHA BILIMORIA

ASTHA BILIMORIA

GUNES BOZKURT, PhD

GUNES BOZKURT, PhD

ANA CASTRO

ANA CASTRO

SAMUEL CHOWDHURY

SAMUEL CHOWDHURY

ERIN CLUTTER

ERIN CLUTTER

MEREDITH COLLINS

MEREDITH COLLINS

ANDREW COSTENOBLE

ANDREW COSTENOBLE

THOMAS CULMAN

THOMAS CULMAN

NATE DAVIS

NATE DAVIS

MAX DENIES, PhD

MAX DENIES, PhD

BRIANA DUNN, PhD

BRIANA DUNN, PhD

MATT FERESTEN

MATT FERESTEN

MICHAEL GILLESPIE, MD

MICHAEL GILLESPIE, MD

EMILY GREEN

EMILY GREEN

EMILY KELTY

EMILY KELTY

TYLER KOWALSKI

TYLER KOWALSKI

CHRISTY KUO, PhD

CHRISTY KUO, PhD

ALYSSA LARSON, PhD